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To the editor: We appreciate the response of dr. Byth to our article1, and agree 
that nonbullous pemphigoid (NBP) deserves more attention in the clinical practice 
guidelines for chronic pruritus, as a rather unknown cause of chronic pruritus in 
elderly patients.2,3 We politely disagree with dr. Byth that NBP patients with 
pruritus without rash should be referred to as ‘pruritus with pemphigoid 
autoantibodies (PPA)’. Firstly, we advocate for NBP as umbrella term for all 
pemphigoid variants without blisters, and believe that introducing the term PPA is 
needless and confusing. Secondly, PPA does not accurately describe the intended 
population of NBP patients without primary skin lesions, since all patients with 
bullous pemphigoid (BP) and NBP experience pruritus and have pemphigoid 
autoantibodies.  
Dr. Byth questioned whether testing for pemphigoid autoantibodies in 
elderly patients with pruritus would be cost-effective. In our opinion, the burden of 
disease in these patients with chronic pruritus is too high to deny them a possible 
diagnosis of NBP and adequate therapy. Therefore, we included pemphigoid in the 
standard diagnostic workup of elderly patients with chronic pruritus.  
We like to emphasize that caution is needed if only ELISA is used as screening 
method, as these have frequent false positive results. The recently published 
article of Wang et al.4 reports positive BP180 and BP230 autoantibodies by ELISA in 
208 patients with a negative skin biopsy for direct immunofluorescence (DIF). 
Various lesion morphologies were described in these patients, most commonly 
dermatitis, but also essential pruritus. The authors conclude that low positive levels 
of BP180 and BP230 autoantibodies should not be overinterpreted as evidence for 
BP in the setting of a negative DIF, and still consider DIF positivity to be the golden 
standard for diagnosis of NBP. 
Recent work of our group assessed this clinical dilemma with a diagnostic 
accuracy study in 1125 patients suspected of NBP or BP, providing minimal 
diagnostic criteria.5 IIF on salt-split skin (SSS) showed a positive predictive value for 
diagnosis of pemphigoid of 99.6%, and therefore plays an essential role for the 
serological diagnosis of pemphigoid. The BP180 NC16A ELISA showed frequent 
false-positivity (11,3%) and is not recommended for initial diagnosis, but only for 
disease monitoring in confirmed patients. The established minimal diagnostic 
criteria consists of a 2 out of 3 rule: (1) pruritus and/or predominant cutaneous 
blisters, (2) linear (n-serrated) IgG and/or C3c deposits by DIF on a skin biopsy 





sample. Thereby, extending the spectrum of pemphigoid with the unrecognized 
nonbullous variant, and allowing a diagnosis with negative DIF.   
Our article complements the study of Wang et al., demonstrating the use 
of the minimal diagnostic criteria in the broad spectrum of NBP. In conclusion, not 
all patients with ‘pruritus with pemphigoid autoantibodies’ with ELISA positivity 
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